Ferronova
Adelaide, Australia· Est.
Ferronova delivers a radiation‑free, nanoparticle‑based lymphatic tracer to enhance precision surgery and imaging for upper GI oncology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Ferronova delivers a radiation‑free, nanoparticle‑based lymphatic tracer to enhance precision surgery and imaging for upper GI oncology.
Oncology
Technology Platform
Mannose‑labelled super‑paramagnetic iron‑oxide nanoparticle (FerroTrace®) for MRI‑visible, magnetometer‑detectable lymph node mapping, optionally combined with ICG NIR imaging.
Opportunities
Expansion of FerroTrace® into other solid‑tumor indications and integration with AI‑driven imaging analysis could broaden market reach and create recurring revenue streams.
Risk Factors
Regulatory approval hinges on robust clinical data; adoption may be slowed by entrenched use of radiocolloids and the need for compatible imaging equipment.
Competitive Landscape
Key competitors include traditional radiocolloid tracers and blue dyes, as well as emerging SPIO agents like Sienna+; Ferronova differentiates through combined MRI visibility, long retention, and radiation‑free operation.